February 2024
ReEngage Therapeutics Joins Texas Medical Center’s 2025 Accelerator for Cancer Therapeutics Read More
ReEngage is a biopharmaceutical R&D company focused
on developing drugs that treat longevity-related diseases.
ReEngage does this by modifying epigenetic targets that are implicated
in aging-related disorders, including neurodegeneration and cancer.
- About ReEngage Therapeutics
- Exclusive licensee of ACSS2 inhibitors in the field of cancer from Epivario Inc.
- Sponsored research agreement with MD Anderson and PI Dr. Eyal Gottlieb, VP Research
- Collaboration with Scripps Florida high throughput screening team led by Dr. Tim Spicer and Dr. Louis Scampia
- Focused on treatments of longevity disorders that impact aging, including cancer and neurodegeneration